Rapamycin was first approved by the FDA for use in transplant patients in the late 1990s. At high doses it suppresses the immune system. At low doses, Kaeberlein says it seems to help tamp down inflammation.
...granted FDA approval to test rapamycin in patients with gum disease — a common condition that tends to accelerate with age...(gum disease is linked to a higher risk of heart disease, and maybe dementia, too)
From NPR
No comments:
Post a Comment